Almost 1,500 pharma firms could miss FMD deadline, warns body in charge
The European Medicines Verification Organisation has warned that almost 1,500 companies are at risk of failure to comply with the Falsified Medicines Directive, and that it will not be held responsible for any consequences that companies may face as a result.
Source: Jonathan Buisson
Around 1,500 pharmaceutical companies are at risk of failure to comply with the Falsified Medicines Directive (FMD) because they have yet to start working with the European Medicines Verification Organisation (EMVO), the body has warned.
The EMVO said that just 841 companies have completed the first stage of connection to the EU Hub — the EU-wide database at the centre of the FMD — which is the beginning of a process known as ‘on-boarding’. It added that it can take up to six months to complete the process, ahead of the February 2019 deadline for completion.
Under the FMD, more than 2,000 pharmaceutical firms with marketing authorisations to supply prescription medicines to the European Economic Area must connect to the Hub and upload to it unique identification data for each pack of medicine they manufacture or repackage.
In a , the EMVO said that of , only 841 companies have completed the first stage of connection: the signing of a participation agreement. Of those, only 106 companies have progressed to become fully connected to the production environment of the EU Hub.
“In January 2018, EMVO announced that the very last opportunity to on-board timely is June 2018,” the letter said.
“Any on-boarding after that date may entail a risk to the company’s compliance with the FMD and consequently to the business too.”
The letter warns companies that the on-boarding process can take up to six months to complete, and that as of the date of the letter, there are only 131 working days before FMD comes into force. It urges companies who have yet to start on-boarding to begin the process as soon as possible, and states that EMVO will not be held responsible or liable for any consequences to companies that may arise from late on-boarding, or failure to on-board.
Citation: The Salvadore DOI: 10.1211/PJ.2018.20205306
Recommended from Pharmaceutical Press
Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£133.00
Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£252.00
Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.£38.00
Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.£43.00
Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.£40.00